SEOUL, November 17 (AJP) - GC Biopharma said Tuesday it has signed an agreement with DongBang Future Tech & Life, a pharmaceutical ingredients maker, to explore domestic production of ionizable lipids, a key material in mRNA vaccines.
The memorandum of understanding signed Monday, concerns of Ionizable lipids, which are a component of lipid nanoparticles (LNP) that protect fragile mRNA and deliver it into cells.
GC Biopharma has filed patents on 12 LNP designs built on its own lipid library: eight high-expression types and four targeted types.
The company has been buying lipid materials through overseas contract research organizations. It expects the partnership to give it a domestic lipid library and speed up its screening of promising candidates.
In 2022, GC Biopharma signed a development and option agreement with Canada’s Acuitas Therapeutics, the LNP developer whose technology went into Pfizer and BioNTech’s COVID-19 vaccine.
Tags: GC Biopharma, DongBang Future Tech & Life, Pfizer, BioNTech, Acuitas Therapeutics, COVID-19 vaccine
The memorandum of understanding signed Monday, concerns of Ionizable lipids, which are a component of lipid nanoparticles (LNP) that protect fragile mRNA and deliver it into cells.
GC Biopharma has filed patents on 12 LNP designs built on its own lipid library: eight high-expression types and four targeted types.
The company has been buying lipid materials through overseas contract research organizations. It expects the partnership to give it a domestic lipid library and speed up its screening of promising candidates.
In 2022, GC Biopharma signed a development and option agreement with Canada’s Acuitas Therapeutics, the LNP developer whose technology went into Pfizer and BioNTech’s COVID-19 vaccine.
Tags: GC Biopharma, DongBang Future Tech & Life, Pfizer, BioNTech, Acuitas Therapeutics, COVID-19 vaccine
Copyright ⓒ Aju Press All rights reserved.